SCHEMBL1560149

SCHEMBL1560149

CCOC(CNCC(C)(C)C)OCC

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566294 0.80 THRB (0.31) THRB
SCHEMBL8315999 0.80 THRB (0.42) THRBLMNA
SCHEMBL13737517 0.76
SCHEMBL2263311 0.75 KDM4E (0.41) THRBLMNA
SCHEMBL24307971 0.71 LMNA (0.39) THRBLMNA
SCHEMBL13167559 0.71 THRB (0.35) THRBLMNA
SCHEMBL10931582 0.71 ANPEP (0.38) THRBLMNA
SCHEMBL2262042 0.70 THRB (0.33) THRBLMNA
SCHEMBL13407590 0.69 ALDH1A1 (0.41)
SCHEMBL7007134 0.69 THRB (0.36) THRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017602-B2 N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy ASTRAZENECA AB (SE) 2011-09-13 US disclosed
US-8017602-B2 N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy ASTRAZENECA AB (SE) 2011-09-13 US disclosed
US-8017602-B2 N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy ASTRAZENECA AB (SE) 2011-09-13 US disclosed
EP-2303873-A1 BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS AstraZeneca AB (SE) 2011-04-06 EP disclosed
US-20100105642-A1 NOVEL COMPOUNDS 409 ASTRAZENECA AB (SE) 2010-04-29 US disclosed
US-20100105642-A1 NOVEL COMPOUNDS 409 ASTRAZENECA AB (SE) 2010-04-29 US disclosed
US-20100105642-A1 NOVEL COMPOUNDS 409 ASTRAZENECA AB (SE) 2010-04-29 US disclosed
WO-2009154557-A1 BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS ASTRAZENECA AB (SE) 2009-12-23 WO disclosed
WO-2009154557-A1 BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS ASTRAZENECA AB (SE) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105642-A1 NOVEL COMPOUNDS 409 GPR119, CYP4B1, CYP4A11 THRB 2488/4885LMNA 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.